Ischemia Reperfusion Injury - Pipeline Review, H2 2015

Is Released
Ischemia Reperfusion Injury - Pipeline Review, H2 2015 Summary Global Markets Direct s, Ischemia
Reperfusion Injury - Pipeline Review, H2 2015, provides an overview of the Ischemia Reperfusion Injurys
therapeutic pipeline. This report provides comprehensive information on the therapeutic development
for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics
assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases. It also reviews key players
involved in the therapeutic development for Ischemia Reperfusion Injury and special features on latestage and discontinued projects. Global Markets Directs report features investigational drugs from
across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data
and information sourced from Global Markets Directs proprietary databases, Company/University
websites, SEC filings, investor presentations and featured press releases from company/university sites
and industry-specific third party sources, put together by Global Markets Direct s team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of
processes that ensures that all the profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box and clinical trials registries
tracking ensure that the most recent developments are captured on a real time basis. The report
enhances decision making capabilities and help to create effective counter strategies to gain
competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered
based on the availability and relevance of data for the indicated disease. Scope - The report provides a
snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury - The report reviews key
pipeline products under drug profile section which includes, product description, MoA and R&D brief,
licensing and collaboration details & other developmental activities - The report reviews key players
involved in the therapeutics development for Ischemia Reperfusion Injury and enlists all their major and
minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of
the Ischemia Reperfusion Injury products under development by companies and universities/research
institutes based on information derived from company and industry-specific sources - Pipeline products
coverage based on various stages of development ranging from pre-registration till discovery and
undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Ischemia Reperfusion Injury pipeline on the basis of target, MoA, route of
administration and molecule type - Latest news and deals relating related to pipeline products Reasons
to buy - Provides strategically significant competitor information, analysis, and insights to formulate
effective R&D development strategies - Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic
initiatives by understanding the focus areas of leading companies - Identify and understand important
and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers
and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective
measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of
Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand business potential and
1

scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the
factors that drove them from pipeline.
with TOC
@ http://www.idatainsights.com/reports-landing-page.php?id=173365/ischemiareperfusion-injury-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173365/ischemia-reperfusion-injury-pipeline-review-h2-2015

Table of Contents

Introduction 7
Global Markets Direct Report Coverage 7
Ischemia Reperfusion Injury Overview 8
Therapeutics Development 9
Pipeline Products for Ischemia Reperfusion Injury - Overview 9
Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis 10
Ischemia Reperfusion Injury - Therapeutics under Development by Companies 11
Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes 14
Ischemia Reperfusion Injury - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Ischemia Reperfusion Injury - Products under Development by Companies 19
Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes 21
Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 23
Alligator Bioscience AB 23
Angion Biomedica Corp. 24
Antipodean Pharmaceuticals, Inc. 25
Biomedica Management Corporation 26
Bolder Biotechnology, Inc. 27
Curatis Pharma GmbH 28
2

Enteris BioPharma, Inc. 29

Erimos Pharmaceuticals, LLC (Inactive) 30
Gilead Sciences, Inc. 31
Ischemix 32
Kowa Company, Ltd. 33
LG Life Science LTD. 34
Omeros Corporation 35
Opsona Therapeutics Limited 36
Peptinnovate Limited 37
Pharming Group N.V. 38
PledPharma AB 39
Prolong Pharmaceuticals 40
Proteo, Inc. (Inactive) 41
Prothix BV 42
Trophos SA 43
Zealand Pharma A/S 44
Ischemia Reperfusion Injury - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 49
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
ADC-1004 - Drug Profile 56
AM/AMBP-1 - Drug Profile 57
Annexin A-1 - Drug Profile 60

ANV-6L15 - Drug Profile 61

APP-103 - Drug Profile 62
BB-3 - Drug Profile 63
BBT-059 - Drug Profile 66
C1 esterase inhibitor (human) - Drug Profile 67
CMX-2043 - Drug Profile 72
CRX-526 - Drug Profile 74
Curaglutide - Drug Profile 75
danegaptide - Drug Profile 76
Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drug Profile 78
EP-80317 - Drug Profile 79
GS-459679 - Drug Profile 80
KN-93 - Drug Profile 81
mangafodipir trisodium - Drug Profile 83
MG-53 - Drug Profile 84
mirococept - Drug Profile 86
MitoQ - Drug Profile 88
Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile 90
Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology Drug Profile 91
Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile 93
MTP-131 - Drug Profile 94
NBD Peptide - Drug Profile 96
NecX - Drug Profile 98
Neutrolide - Drug Profile 99
NP-202 - Drug Profile 101
Oligonucleotide for Oncology and Cardiovascular - Drug Profile 103

OMS-721 - Drug Profile 104

OPN-305 - Drug Profile 106
PAC-G31P - Drug Profile 108
PIN-201601 - Drug Profile 110
pitavastatin NP - Drug Profile 111
PRO-02 - Drug Profile 112
R-190 - Drug Profile 113
Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug
Profile 115
Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation
Syndrome and Ischemic Organ Injury - Drug Profile 116
Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug
Profile 117
Recombinant Proteins for Ischemia Reperfusion Injury - Drug Profile 118
Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 119
Recombinat Protein to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion
Injury - Drug Profile 120
Sanguinate - Drug Profile 121
Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion
Injury - Drug Profile 123
Small Molecules for Ischemia Reperfusion Injury - Drug Profile 124
Small Molecules for Ischemia Reperfusion Injury - Drug Profile 125
Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile 126
Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile 127
Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 128
SMTP-7 - Drug Profile 129
Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile 130
Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile 131
terameprocol - Drug Profile 132

tiprelestat - Drug Profile 134

TRO-40303 - Drug Profile 137
UCF-101 - Drug Profile 139
UWA-TAT - Drug Profile 140
Ischemia Reperfusion Injury - Recent Pipeline Updates 141
Ischemia Reperfusion Injury - Dormant Projects 160
Ischemia Reperfusion Injury - Discontinued Products 164
Ischemia Reperfusion Injury - Product Development Milestones 165
Featured News & Press Releases 165
Appendix 173
Methodology 173
Coverage 173
Secondary Research 173
Primary Research 173
Expert Panel Validation 173
Contact Us 173
Disclaimer 174"

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173365/ischemiareperfusion-injury-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
6

Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects